News
Public · Published
Pharma firms closed biopharma buyouts worth over a hundred billion dollars in the first half of the year, racing to replace top selling medicines worth around $400 billion before patents expire. Leah Bennett of Concurrent explains
Pharmaceutical companies completed biopharma acquisitions worth over a hundred billion dollars in the first half of the year, aiming to replace top-selling medicines worth around $400 billion before their patents expire, according to Leah Bennett of Concurrent.
Published:
Updated:
What happened
Pharmaceutical companies completed biopharma acquisitions worth over a hundred billion dollars in the first half of the year, aiming to replace top-selling medicines worth around $400 billion before their patents expire, according to Leah Bennett of Concurrent.
Confirmed
Global impact / market context
Buying biopharma companies gives pharma firms new drugs to sell as older medicines lose patent protection, which means cheap copies can cut their revenue. That spending protects future sales and profits, but using large amounts of cash or borrowed money can reduce the cash available for other needs.
Analyst inference
This deal wave shows pharma firms are under pressure because about $400 billion of medicines face patent expiry. Rivals, suppliers, and buyers of healthcare assets could see changing competition, while investors may reposition based on which firms fill their revenue gaps fastest.
Analyst inference
What to watch
- The article states that biopharma buyouts worth over a hundred billion dollars closed in the first half of the year and that roughly $400 billion of top-selling medicines face patent expiry. Confirmed
- Watch whether pharma firms propose more acquisitions, partnerships, or licensing deals to replace revenue from medicines losing patent protection, and whether they use cash or borrowed money to fund them. Proposed
- Watch whether these acquisitions produce new approved medicines or cost cuts before older drugs lose protection, since weak results could pressure drugmaker revenues, profits, and investor confidence. Analyst inference